Cargando…

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aimed to compare the occurrence of breakthrough bleeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy-Mendelovich, Sarina, Brutman-Barazani, Tami, Budnik, Ivan, Avishai, Einat, Barg, Assaf A., Levy, Tamara, Misgav, Mudi, Livnat, Tami, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509656/
https://www.ncbi.nlm.nih.gov/pubmed/34640320
http://dx.doi.org/10.3390/jcm10194303
_version_ 1784582394898022400
author Levy-Mendelovich, Sarina
Brutman-Barazani, Tami
Budnik, Ivan
Avishai, Einat
Barg, Assaf A.
Levy, Tamara
Misgav, Mudi
Livnat, Tami
Kenet, Gili
author_facet Levy-Mendelovich, Sarina
Brutman-Barazani, Tami
Budnik, Ivan
Avishai, Einat
Barg, Assaf A.
Levy, Tamara
Misgav, Mudi
Livnat, Tami
Kenet, Gili
author_sort Levy-Mendelovich, Sarina
collection PubMed
description Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aimed to compare the occurrence of breakthrough bleeding at different time points, starting from emicizumab initiation. This longitudinal prospective observational cohort study included HA patients (n = 70, aged 1 month to 74.9 years) that completed at least 18 months of follow-up in our center. We analyzed the number of spontaneous and traumatic bleeds during selected time points of the study (“bleeding periods”). The percentage of traumatic and spontaneous bleeding episodes was not significantly different among “bleeding periods” (P = 0.053 and P = 0.092, respectively). Most trauma-related treated bleeds resulted from either hemarthrosis (53%) or head trauma (33%). Spontaneous bleeding episodes were mostly hemarthroses (80%). Potential associations of the patients’ age, annualized bleeding rate before emicizumab treatment, and the presence of inhibitors with spontaneous bleed occurrence were analyzed with binomial logistic regression. The odds of bleeding while on emicizumab increased by a factor of 1.029 (P = 0.034) for every one year of age. Conclusions: Our real-world data revealed that the risk of bleeding persists, especially in older patients, despite therapy with emicizumab. These data may help clinicians in counselling their patients and in planning their management.
format Online
Article
Text
id pubmed-8509656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85096562021-10-13 Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab Levy-Mendelovich, Sarina Brutman-Barazani, Tami Budnik, Ivan Avishai, Einat Barg, Assaf A. Levy, Tamara Misgav, Mudi Livnat, Tami Kenet, Gili J Clin Med Article Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aimed to compare the occurrence of breakthrough bleeding at different time points, starting from emicizumab initiation. This longitudinal prospective observational cohort study included HA patients (n = 70, aged 1 month to 74.9 years) that completed at least 18 months of follow-up in our center. We analyzed the number of spontaneous and traumatic bleeds during selected time points of the study (“bleeding periods”). The percentage of traumatic and spontaneous bleeding episodes was not significantly different among “bleeding periods” (P = 0.053 and P = 0.092, respectively). Most trauma-related treated bleeds resulted from either hemarthrosis (53%) or head trauma (33%). Spontaneous bleeding episodes were mostly hemarthroses (80%). Potential associations of the patients’ age, annualized bleeding rate before emicizumab treatment, and the presence of inhibitors with spontaneous bleed occurrence were analyzed with binomial logistic regression. The odds of bleeding while on emicizumab increased by a factor of 1.029 (P = 0.034) for every one year of age. Conclusions: Our real-world data revealed that the risk of bleeding persists, especially in older patients, despite therapy with emicizumab. These data may help clinicians in counselling their patients and in planning their management. MDPI 2021-09-22 /pmc/articles/PMC8509656/ /pubmed/34640320 http://dx.doi.org/10.3390/jcm10194303 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Levy-Mendelovich, Sarina
Brutman-Barazani, Tami
Budnik, Ivan
Avishai, Einat
Barg, Assaf A.
Levy, Tamara
Misgav, Mudi
Livnat, Tami
Kenet, Gili
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title_full Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title_fullStr Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title_full_unstemmed Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title_short Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
title_sort real-world data on bleeding patterns of hemophilia a patients treated with emicizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509656/
https://www.ncbi.nlm.nih.gov/pubmed/34640320
http://dx.doi.org/10.3390/jcm10194303
work_keys_str_mv AT levymendelovichsarina realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT brutmanbarazanitami realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT budnikivan realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT avishaieinat realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT bargassafa realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT levytamara realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT misgavmudi realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT livnattami realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab
AT kenetgili realworlddataonbleedingpatternsofhemophiliaapatientstreatedwithemicizumab